KRAS and cancer: Within the KRAS G12R mutated subset, survival rates were numerically longer for patients with cancers harboring co-occurring core HRR defects (24.2 vs. 19.9 months, P = .60) or any HRR defects (21.9 vs. 19.9 months, P = 0.41), although statistical significance was not observed (Supplementary Table S4).